In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency.

CRISPR (clustered regularly interspaced short palindromic repeats) genome editing holds promise in the treatment of genetic diseases that currently lack effective long-term therapies. Patients with alpha-1 antitrypsin (AAT) deficiency develop progressive lung disease due to the loss of AAT's antiprotease function and liver disease due to a toxic gain of function of the common mutant allele. However, it remains unknown whether CRISPR-mediated AAT correction in the liver, where AAT is primarily expressed, can correct either or both defects. Here we show that AAV delivery of CRISPR can effectively correct Z-AAT mutation in the liver of a transgenic mouse model. Specifically, we co-injected two AAVs: one expressing Cas9 and another encoding an AAT guide RNA and homology-directed repair template. In both neonatal and adult mice, this treatment partially restored M-AAT in the serum. Furthermore, deep sequencing confirmed both indel mutations and precise gene correction in the liver, permitting careful analysis of gene editing events in vivo. This study demonstrates a proof of concept for the application of CRISPR-Cas9 technology to correct AAT mutations in vivo and validates continued exploration of this approach for the treatment of patients with AAT deficiency.

[1]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[2]  T. Flotte,et al.  Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. , 2013, The Journal of clinical investigation.

[3]  Pooja Chaudhari,et al.  Efficient and allele-specific genome editing of disease loci in human iPSCs. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Zhiping Weng,et al.  Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. , 2017, Gastroenterology.

[5]  R. Crystal,et al.  Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease. , 2016, Annals of the American Thoracic Society.

[6]  G. Gao,et al.  Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses , 2018, Nature Communications.

[7]  T. Flotte,et al.  5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[9]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[10]  Wei Tang,et al.  Correction of a genetic disease in mouse via use of CRISPR-Cas9. , 2013, Cell stem cell.

[11]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[12]  Minerva E. Sanchez,et al.  Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice. , 2018, Human gene therapy.

[13]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[14]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[15]  Prashant Mali,et al.  A multifunctional AAV–CRISPR–Cas9 and its host response , 2016, Nature Methods.

[16]  Wen Xue,et al.  CRISPR–Cas-related technologies in basic and translational liver research , 2018, Nature Reviews Gastroenterology & Hepatology.

[17]  Lili Wang,et al.  Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy , 2009, Proceedings of the National Academy of Sciences.

[18]  Jacob E Corn,et al.  Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering , 2017, eLife.

[19]  F. Callea,et al.  Alpha‐1‐antitrypsin deficiency: from genoma to liver disease. PiZ mouse as model for the development of liver pathology in human , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[20]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[21]  T. Flotte,et al.  Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno‐associated virus (rAAV1) vector , 2006, The journal of gene medicine.

[22]  T. Flotte,et al.  Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA Profiles , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Robert Langer,et al.  Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. , 2018, Nature chemical biology.

[24]  T. Flotte,et al.  Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Eriksson,et al.  Liver disease in adults with alpha-1 -antitrypsin deficiency. , 1972, The New England journal of medicine.

[26]  Hao Yin,et al.  CRISPR-mediated direct mutation of cancer genes in the mouse liver , 2014, Nature.

[27]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[28]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[29]  T. Flotte,et al.  Current status of gene therapy for α-1 antitrypsin deficiency , 2015, Expert opinion on biological therapy.

[30]  Jessica Zucman-Rossi,et al.  Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas , 2015, Nature Genetics.

[31]  T. Flotte,et al.  Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  M. Drumm,et al.  Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. , 1993, The Journal of biological chemistry.

[33]  R. Crystal,et al.  Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. , 1987, The New England journal of medicine.